Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR-T cells targeting mesothelin and B7-H3
- Development stage
- Unknown
- Lead developer
- The Seventh Affiliated Hospital, Sun Yat-Sen University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CAR-T cells targeting mesothelin and B7-H3 is an autologous chimeric antigen receptor (CAR) T-cell therapy designed to simultaneously target two tumor-associated antigens: mesothelin (MSLN) and B7-H3 (CD276). Mesothelin is a cell-surface glycoprotein highly expressed in several solid malignancies, including pancreatic and breast cancers, while B7-H3 is an immune checkpoint member of the B7 family that is frequently overexpressed in the tumor microenvironment and linked to immune evasion. By utilizing a dual-targeting approach, this therapy aims to mitigate antigen escape and enhance the precision and potency of T-cell-mediated killing against heterogeneous solid tumors. The Seventh Affiliated Hospital of Sun Yat-sen University is investigating this candidate in early-phase clinical trials for patients with advanced pancreatic cancer and triple-negative breast cancer who have exhausted standard systemic treatment options.
- Other names
- mesothelin/B7-H3 dual-targeting CAR-T cellsMSLN/B7-H3 CAR-T
02
Targets
MesothelinB7-H3
Beyond the preview
Go deeper on CAR-T cells targeting mesothelin and B7-H3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR-T cells targeting mesothelin and B7-H3.